Effects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic hepatitis B patients

Basit Öğe Kaydı
dc.contributor.authorKara, A., V
dc.contributor.authorYildirim, Y.
dc.contributor.authorOzcicek, F.
dc.contributor.authorAldemir, M. N.
dc.contributor.authorArslan, Y.
dc.contributor.authorBayan, K.
dc.contributor.authorCelen, M. K.
dc.date.accessioned2024-04-24T17:33:40Z
dc.date.available2024-04-24T17:33:40Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground and study aims : The aim of this study was to enlighten the controversy about the renal safety of entecavir, tenofovir, and telbivudine treatments in chronic hepatitis B (CHB) patients by comparing these treatments in real-world conditions. Patients and methods: We retrospectively enrolled 104 treatment-naive patients with CHB monoinfection into our study. Patients were treated with entecavir monotherapy (n=38), tenuflivir monotherapy (n=35), or telbivudine monotherapy (n=31). We then compared and statistically analyzed the effects of these drugs on the estimated glomerular filtration rate (eGFR) over a 24-month follow-up period. Results : In the entecavir group, time-dependent change in eGFR was not statistically significant (p = 0.357). There was a statistically significant increase in eGFR in the telbivudine group at 12 months (p < 0.001) and at 24 months (p < 0.001) and, in contrast, a statistically significant decrease in the tenofovir group at 12 months (p < 0.001) and at 24 months (p < 0.001). There was no significant relationship between entecavir and eGFR change (p = 0.763). We found that tenofovir and telbivudine were independent predictors of eGFR change (decrease in eGFR, p < 0.001 and increase in eGFR, p = 0.001, respectively) Conclusions : We recommend close follow-up of renal functions, especially for patients treated with tenofovir. Telbivudine was superior to the other drugs in terms of renal function. We conclude that an individualized therapy program considering treatment efficacy and side effects is the best option for patients.en_US
dc.identifier.endpage277en_US
dc.identifier.issn1784-3227
dc.identifier.issue2en_US
dc.identifier.pmid31314188
dc.identifier.scopus2-s2.0-85068912915
dc.identifier.scopusqualityQ3
dc.identifier.startpage273en_US
dc.identifier.urihttps://hdl.handle.net/11468/20795
dc.identifier.volume82en_US
dc.identifier.wosWOS:000474250900006
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherUniv Catholique Louvain-Uclen_US
dc.relation.ispartofActa Gastro-Enterologica Belgica
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectChronic Hepatitis Ben_US
dc.subjectEstimated Glomerular Filtration Rateen_US
dc.subjectEntecaviren_US
dc.subjectTenofoviren_US
dc.subjectTelbivudineen_US
dc.titleEffects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic hepatitis B patientsen_US
dc.titleEffects of entecavir, tenofovir and telbivudine treatment on renal functions in chronic hepatitis B patients
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu